baber/WOPTO huggingface dataset:
Patent AU-PR606801-A0 (AU)
Title: Apparatus for the production of extended meat products
IPC: A22C21/00
Filed: 2001-07-03
Abstract: An apparatus (10) for the production of meat products includes a support structure (12). A container (14) is mounted on the support structure (12). A conveyor (20) has a first, upstream end (20.1) in communication with the container (14) and a second, downstream end (20.2) arranged downstream of the first end (20.2) and outside the container (14). A comb (34) is arranged downstream of the second end (20.2) of the conveyor (20) for working meat pieces conveyed to the comb (34) by the conveyor (20). The comb (34) is operable independently of the conveyor (20). A processing station (40) is arranged downstream of the comb (34), the processing station (40), together with the comb (34), processing the meat to obtain a desired finished product.
Patent FI-20000985-A0 (FI)
Inventor: JAY DAVE
IPC: F02M55/00
Filed: 2000-04-27
Abstract: In an arrangement for locating fuel leak in connection with a large combustion engine (5), particularly a large diesel engine, fuel is fed into several fuel injectors (8) from a common fuel space (9, 10), and a fuel injection system comprises a double wall (15) fuel pipe system (11, 12, 3), which in turn comprises an inner flow space (14) for fuel and outer flow space (16) for possibly leaking fuel. The fuel injection system comprises at least one leaking fuel detection arrangement (18, 18', 18", 18"') in connection with an outer flow channel (16) of at least one section of the pipe system (11, 12, 13).   <IMAGE>
Patent FI-20002363-A0 (FI)
Inventor: KAUPPINEN ESKO
IPC: A61M15/00
Filed: 2000-10-27
Abstract: A device for delivering a powdered medicament by inhalation comprises an air inlet passage having low pressure-drop and low turbulence for stabilizing air flow before aerosolization, a dosing cup in the region of reduced air velocity to delay aerosolization, a high pressure drop throat to generate a high velocity flow, a rapidly expanding diverging passage to create a free jet of air with high turbulence and an outlet passage having large cross-sectional area to control the rate of dissipation of the free jet. The device is simple yet capable of consistently providing uniform and effective powder aerosolization and deagglomeration over a variety of patient inhalation profiles.
Patent FI-20011940-A0 (FI)
IPC: B03D1/16
Filed: 2001-10-04
Abstract: The present invention relates to a froth flotation mechanism located in a flotation cell, comprising a directional element suspended from the lower end of a hollow shaft extending to the lower section of the cell and vertical vanes attached to said directional element, which extend above and below the directional element and horizontally beyond the directional element. The substantially horizontal circular plate of the directional element is symmetrically attached around the shaft at its centre and the outer edge of the central plate is bent downwards to form the lap of the guiding part. The gas spreading plate is located on the inner side of the lap. The flotation cell is comprised of a cylindrical lower section, a middle section located above it in the form of a truncated cone widening upwards, and a cylindrical upper section attached to the top of it.
Patent FI-20030760-A0 (FI)
Inventor: NAQVI SHAMIM
IPC: H04W76/04
Filed: 2003-05-21
Abstract: A proxy switch, communication methods, and communication logic for use in a mobile network are described. A proxy switch is deployed between a base station subsystem and a mobile station center. It receives signaling messages and either retransmits them, blocks them, converts them, or siphons them to an alternative network. Besides providing an ability to offload mobile traffic it provides a platform for new communication services. A proxy switch includes signaling message handling logic for sending and receiving signaling messages to and from the MSC on a first signaling link and sending and receiving messages to and from the BS on a second signaling link; wherein the second link has a mapped correspondence to the first link. Message interception logic detects whether a signaling message from an MSC is a COO, indicating that the MSC will not receive signaling messages on the first signaling link. The message interception logic also prevents the COO from being forwarded to the BS and generates and sends a change over acknowledge (COA) message to the MSC. Signaling message redirection logic receives signaling messages on the second signaling link and provides control information contained therein to the alternative communication network after the message interception logic detects the COO; and bearer circuit redirection logic receives information from a bearer circuit corresponding to the second signaling link and directs the information to the alternative communication network.
Patent IL-100052-A0 (IL)
Title: Charged asymmetric mosaic membranes and their preparation
IPC: B01D69/02
Filed: 1991-11-14
Abstract: The present invention relates to semipermeable mosaic polymer membranes of asymmetric structure and with a macroscopic distribution of the mosaic-forming anionic and cationic charges (sites). The membranes can be prepared by casting a polymer solution of an optionally charged matrix-forming polymer and at least one precursor polymer, incompatible with the matrix-forming polymer, in a selected solvent, into a film, forming a skin on one side of the film, precipitating the skinned film to form the asymmetric membrane and charging it by chemical reactions to introduce or complete their mosaic structure. These membranes have good permeability for electrolytes, such as salts of mono- or polyvalent inorganic acids, while retaining low molecular weight organic solutes.
Patent IL-105456-A0 (IL)
Title: Attenuated respiratory syncytial virus vaccine compositions
IPC: C12N7/00
Filed: 1993-04-19
Abstract: The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.
Patent IL-118890-A0 (IL)
Title: CTLA4 mutant molecules method for their preparation and uses thereof
IPC: C12N15/12
Filed: 1996-07-18
Abstract: The invention provides CTLA4 mutant molecules as ligands for the B7 antigen. Methods are provided for expressing CTLA4 mutant molecules as soluble, functional molecules, for preparing CTLA4 mutant fusion proteins, and for using these soluble molecules to regulate T cell interactions and immune responses mediated by such interactions. <IMAGE>
Patent IL-132214-A0 (IL)
Title: Use of zinc hyaluronate against peptic ulcer
IPC: A61K47/48
Filed: 1998-04-28
Abstract: The invention relates to pharmaceutical compositions against peptic ulcer as well as to a method of treating peptic ulcer. The compositions contain and the method of treatment employs zinc hyaluronate as an active ingredient having a molecular weight in the range of 500,000 to 1,200,000 daltons.
Patent IL-132269-A0 (IL)
Title: Process and intermediates for a beta3-adrenergic receptor agonist
IPC: C07D213/16
Filed: 1999-10-07
Abstract: The instant invention relates to intermediates of Formula II, <CHEM> wherein R<1>, R<2> and R<3> are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for preparing compounds of Formula III, <CHEM> and enantiomers thereof, wherein R<2>, R<3> and R<4> are as defined in the specification. Compounds of Formula II and Formula III are intermediates in the preparation of a potent  beta 3 adrenergic receptor agonist. The instant invention also relates to processes for preparing the  beta 3 adrenergic receptor agonist using the compounds of Formula II and Formula III.
Patent IL-135578-A0 (IL)
Title: Compositions and methods for treating lysosomal storage disease
IPC: A61K35/76
Filed: 1998-10-29
Abstract: The present invention provides a biologically active human lysosomal enzyme to cells deficient therein comprising introducing into the cells a vector comprising and expressing a transgene encoding the biologically active human lysosomal enzyme, wherein the vector is taken up by the cells, the transgene is expressed therein and biologically active enzyme is produced.
Patent IL-138820-A0 (IL)
Title: Retaining wall block system
IPC: E02D5/00
Filed: 2000-02-04
Abstract: A wall block system having a plurality of blocks (5) suitable for use in constructing a wall from multiple courses of the blocks stacked one upon the other, the wall block system comprising: first and second blocks, each block having a thickness, width and length; each block having an upper surface (8) spaced apart from a lower surface (10), thereby defining the block thickness, the upper surface (8) having a plurality of pin receiving apertures (22a,22b,22c,72), the lower surface (10) having a channel (23,73); each block having opposed first (12) and second faces (14), thereby defining the block length; each block having opposed side surfaces (16,18), thereby defining the block width as measured between midpoints of the side surfaces, a width of the first blocks being different than a width of the second blocks; and a plurality of pins, each pin (80) having a head portion (76) and a body portion (78), the body portion of each pin being sized to be received in a pin receiving aperture (72), the head portion being larger than a pin receiving aperture and being sized to be received in a channel (73), the pins being configured such that when the wall is constructed from the wall block system, the head portion is configured to be received within the channel of the lower surface of a block in a first course of the wall and the body portion is configured to be received in one of the pin receiving apertures of a block in a next lower course of the wall.
Patent IL-150727-A0 (IL)
Title: Intrinsically safe traffic control system, method and apparatus optimezed for inherent-polarity traffic signals
IPC: G08G1/095
Filed: 2001-01-20
Abstract: The present invention demonstrates that light-emitting diodes (LEDs) have electrical characteristics that can be used to dramatically reduce the complexity and cost of the traffic signaling equipment needed to control the array of signals to give the right of way to the vehicles in a given intersection. This also enhances the energy saving features of LEDs by relocating the power source to the traffic signal control system and the electric conditioning devices to the signal position, increasing the energy efficiency of the whole intersection. One benefit is "intrinsic safety' based on a method for power distribution to the signals that does not allow failure modes that could cause accidents. The system ensures that simultaneous green or yellow signals on crossed streets are impossible even though the signals are connected to the same power lines, allowing also the use of a bus connection topology with a command driven control of the ON/OFF state for each individual light or signal. This "phase conflict prevention' is safer and simpler than the prior art and also eliminates the need of the independent monitoring equipment usually required to prevent such hazardous conditions. Also there is a large reduction in the number of wires resulting in even greater controller simplicity due to the ability of controlling a larger number of signals with a given number of electric conductors than in the prior art.
Patent IL-164969-A0 (IL)
Title: Injection device
IPC: A61M5/28
Filed: 2004-11-01
Abstract: An injection device is for use with a syringe having a bore extending from an end surface, a needle communicating with the bore through the end surface and a dispensing piston movable in the bore towards the end surface. The injection device includes a housing having an opening, a resilient member for biasing the syringe and needle inwardly of the housing, a drive element movable towards the one end so as to move the needle out of the opening against the bias of the resilient member, a delatch mechanism operable to release the syringe such that the needle moves inwardly of the housing, and a drive coupling. The drive coupling gradually reduces in length such that, after the drive element has moved the dispensing piston to the end surface, the drive element continues to move to the dispensing piston at the end surface.
Patent IL-185487-A0 (IL)
Title: Technique for testing peers in multicast network domain
Filed: 2007-08-23
Abstract: A technique for testing peer nodes in a multicast domain (such as an access network) interconnected with an Ethernet network via an Intermediate Bridge (IB), especially helpful when an individual MAC address of a destination peer node is unknown. The technique comprises a) issuing a Connectivity Fault Management (CFM) message from the Ethernet network, and introducing into the CFM message alternative destination data being different than the individual MAC address of the destination peer node; b) utilizing the alternative destination data, at the IB, for determining topological position or address of the destination peer node, and c) forwarding contents of the CFM message only to the destination peer node.
Patent IL-196315-A0 (IL)
Title: Medicament for the enhancement of cognitive function and neuroprotection
Filed: 2009-01-01
Abstract: The invention relates the use of 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazole-3-yl)piperidin-1-yl]ethyl-amino}-2-methyl-3-(2H)pyridazinone of the Formula (I) or pharmaceutically acceptable salts thereof for the preparation of medicaments suitable for the improvement of cognitive function or obtaining neuroprotective effect. The medicaments containing 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazol-3-yl)piperidin-1-yl]ethyl-amino}-2-methyl-3-(2H)pyridazinone of the Formula (I) or therapeutically acceptable salt thereof can be used for the treatment or prevention of neuronal death, mental decline, sclerosis multiplex, Creuzfeld-Jacobs disease, Huntington-syndrome, amyotrophic lateral sclerosis, Parkinson-disease, memory disturbance, loss of memory, amnesia, stroke or for the improvement of memory function or learning ability.
Patent RO-127489-A0 (RO)
Title: General use disinfectant-antiseptic
Inventor: COMAN IOAN
IPC: A61K9/08
Filed: 2011-06-27
Abstract: The invention relates to a disinfecting-antiseptic formulation for general use to be employed for destroying microorganisms on the skin surface and on inanimate objects, as well. According to the invention, the product comprises 1...80% concentrated isopropyl alcohol, 0.2...20 ml% benzalkonium chloride, 0.1...10 ml% clorhexidine digluconate, 0.5...5 ml% of 1% methylene blue solution and distilled water for the remainder up to 100%, the percentage being expressed by weight.
Patent RO-129020-A0 (RO)
Title: Process for determining the caloric power of wooden biomass using a calorimeter bomb provided with its own software
Inventor: LUNGULEASA AUREL
IPC: G01K17/00
Filed: 2013-05-07
Abstract: The invention relates to a process for determining the caloric power of wood and other lignocellulose materials intended to be used for combustion. According to the invention, the process uses a calorimeter bomb provided with its own determination software and consists in drying a wooden sample (1) to be tested in a laboratory oven, which is kept in an exsiccator, then connected to a cotton thread (2), put in a crucible (3) of a calorimeter bomb, connected to a nickeline test thread (4), the crucible (3) is connected to a cover (6) of the calorimeter bomb by two electrodes (7, 8), the cover (6) continuing with some electric wires (9, 10) for coupling the calorimeter bomb and, by screwing the cover (6) in, the bomb (11) is coupled by a socket (12) to an oxygen cylinder (Bo), then the bomb (Bo) is introduced into a calorimeter (Cu), the two electric wires (9, 10) are coupled, the cover of the calorimeter (Cu) is closed and a thermostat (T) is introduced to determine the temperature.
Patent RO-130817-A0 (RO)
Title: Process and technological installation for obtaining probiotic nectar from pumpkin and product obtained thereby
Inventor: MORARU DANA IULIA
IPC: A23C9/133
Filed: 2014-10-03
Abstract: The invention relates to a process and a technological installation for obtaining probiotic nectar from pumpkin and to the product obtained thereby. According to the invention, the process comprises the storage, washing and cutting the pumpkins into quarters, manual separation of seeds, weighting, shredding, pasteurization at 90...95°C for 10...15 min, fine grinding and mashing to form a puree which is then diluted and homogenized into a nectar subjected to fermentation at 37°C, followed by cooling at 5°C, packaging and storing at 5±1°C. The installation, as claimed by the invention, comprises a washing machine (2), a machine for cutting pumpkins into quarters (3), a working line (4), a conveyor with profiled plates (6), a trough-like shredding machine (8), a pasteurization equipment (9), a disperser (10) for making the puree, a pump (11) with rotary pistons, a pulper (12) for removing wastes, a pump (14) with rotary pistons, a mixer (15) of the ejector type for diluting the puree, a homogenizer (16) for making the nectar, a fermentation module (18) which also ensures the cooling, a packaging machine (22) and a CIP-type hygienization system. The product obtained in the above mentioned installation, as claimed by the invention, is a probiotic pumpkin nectar with 9.3...10 log CFU/ml, with a controlled dry matter content of 3...4%, with a particle size 100 μ m, at the most, with uniform texture, an acidity of 9.5...11.2 g of lactic acid/100 g dm, with reduced content of reducing sugars (22...27 g of glucose/100 g dm).
Patent RO-130380-A0 (RO)
Title: Fractal antenna stripline
Inventor: MORARIU GHEORGHE
IPC: H01Q1/36
Filed: 2014-10-27
Abstract: The invention relates to a fractal antenna in the microwave field, recommended for the broadband mobile telephony. According to the invention, the antenna is made in fractal architecture, with elements of resonance as closed and open frames, respectively, the frames being divided into two identical capacitively coupled semi-frames.
Patent RO-132310-A0 (RO)
Title: Implant structure, double layer thin film coating and process for functionalization of osseous and dental implant surface
Inventor: FLOROIAN LAURA
IPC: C23C14/06
Filed: 2017-05-31
Abstract: The invention relates to an osseous implant structure and to a process for preparing the same. The claimed structure comprises a metal substrate (5) of stainless steel having a content of 0.013...0.030% C, 0.80...1.73% Mn, 0.3...0.7% Si, 0.019...0.036% P, having a grain size of 10...764 μm, a biocompatible polymer layer (13) of polymethyl methacrylate type having a thickness of 300 nm, a layer (14) formed of bioactive glass from the system SiO-NaO-KO-CaO-MgO-POin admixture with a wide-spectrum antibiotic or a natural plant extract with antimicrobial effect, having a thickness of 300 nm and a hydroxyapatite coating layer (16) which allows rapid osseointegration. The claimed process consists in depositing thin layers by means of matrix-assisted pulsed laser evaporation method, resulting in a thin film structure adherent to the substrate, with controlled thickness at monolayer level.
Patent AP-2001002242-A0 (AP)
Title: Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy.
Inventor: BRYANS JUSTIN STEPHEN
IPC: C07C55/28
Filed: 2000-11-08
Abstract: The present invention is directed to a method for the prophylactic and therapeutic treatment of diabetic retinopathy. The method involves the administration of formulae(i),(ii),(iii)of the branch chain amino acid-dependant amino-transferase (bcat)pathway to an animal,pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the retina for diabetic retinopathy prophylactically or therapeutically. The present invention is also directed to several novel inhibitors of formula (iv)of the bcat pathway. In formulae (i-iv),n,m,x and r1-r13 have the meanings given in the descrption.
Patent AP-2002002430-A0 (AP)
Title: Metal-containing compositions, preparations and uses.
Inventor: HICKOK STEPHEN SPAULDING
IPC: A61K9/08
Filed: 2000-08-31
Abstract: A metal-containing composition substancially comprising (i)at least one water soluble metal compound which forms metal ions when dissolved in water, (ii)at least one metal ion modifier as herein defined, (iii)at least one acid, and (iv)water said composition having a ph of less than 6 and an eletrolytic potential in axcess of 10 millivolts. Such compositions have uses in the prevntion and/or treatment of pathogenic disease or disorder,as foodstuff supplements, in the treatment by disnfection of meat and other foodstuffs, in the coating, sealing and plating of metals, and treatment of water and sewage.
Patent MC-1552-A1 (MC)
Inventor: SMITH KENDALL O
IPC: A61K31/52
Filed: 1983-11-02
Abstract: The combination of 9-[[2-hydroxy-1-(hyroxymethyl)-ethoxy]methyl]guanine, or a pharmaceutically acceptable salt thereof and interferon can show synergy in activity against herpesvirus infections.
Patent HU-208102-A1 (HU)
Inventor: NEGYESSY LASZLO
IPC: C05G3/00
Filed: 1991-03-01
Abstract: A találmány szerint 58-64 t%, előnyösen 62 t% felaprított megdarált tőzeget, 8-12 t%, előnyösen 10 t% természetes eredetű szervestrágyát 8-12 t%, előnyösen 10 t% folyékony halmazállapotú vinaszt, 8-12 t%, előnyösen 10 t% iparilag hasznosíthatatlan bauxitásványt, vagy vörösiszapot, 4-6 t%, előnyösen 5 t% középkötött homokos talajt vagy homokot, 241%, előnyösen 3 t% faszenet homogénen Összekeverünk, a keveréket érlelőprizmákban 1-3 hónapig érleljük. Az érlelési idő alatt legalább kétszer átforgatjuk. HU 208 102 A A leírás terjedelme: 6 oldal
Patent MA-21027-A1 (MA)
IPC: C07D513/04
Filed: 1987-07-02
Abstract: A compound of the general formula I;    <IMAGE>  (I)  in which R is hydrogen or a halogen or an alkyl, alkyloxy, alkylthio, trifluoromethyl, amino, alkylamino, dialkylamino, hydroxy, cyano, carboxy, alkylsulphinyl, alkylsulphonyl, sulphamido, alkylsulphamido, dialkylsulphamido, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, phenylcarbamoyl, diphenylcarbamoyl, pyridylcarbamoyl, dipyridylcarbamoyl, benzyl, alkylcarbonyl, benzoyl, alkyloxycarbonyl, phenoxycarbonyl, alkylcarbonyloxy, benzoyloxy, alkylcarbonylamino, benzamido, phenyl, phenoxy or phenylthio group, X is oxygen or sulphur or an imino, alkylimino, phenylimino, benzylimino, sulphinyl, sulphonyl, carbonyl, carbonylmethylene, methylenecarbonyl, carbonylvinylene or vinylenecarbonyl group, or X represents a valency bond or a straight-chain alkylene group containing 1 to 4 carbon atoms and Ar is a phenyl, naphthyl, pyridyl, quinolinyl, isoquinolinyl, thienyl, benzothienyl, thieno[3,2-b]thien-2-yl or thieno[2,3-b]thien-2-yl group, it being possible for the group Ar to be unsubstituted or substituted with one or more halogen or alkyl, alkyloxy, alkylthio, trifluoromethyl, amino, alkylamino, dialkylamino, hydroxy, cyano, carboxy, alkylsulphinyl, alkylsulphonyl, sulphamido, alkylsulphamido, dialkylsulphamido, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, phenylcarbamoyl, diphenylcarbamoyl, pyridylcarbamoyl, dipyridylcarbamoyl, benzyl, alkylcarbonyl, benzoyl, alkyloxycarbonyl, phenoxycarbonyl, alkylcarbonyloxy, benzoyloxy, alkylcarbonylamino or benzamido group; each alkyl moiety containing 1 to 4 straight- or branched-chain carbon atoms; the compound being in separate enantiomeric form or mixtures thereof or a pharmaceutically acceptable salt thereof is useful in the treatment of all the pathological conditions in which PAF-acether may be directly or indirectly implicated.